Pancreatic Cancer Clinical Trial
— CLAUDIO-01Official title:
A Multicentric Phase 1/2 Trial to Evaluate the Safety and Efficacy of SOT102 as Monotherapy and in Combination With Standard of Care Treatment in Patients With Gastric and Pancreatic Adenocarcinoma
Verified date | November 2023 |
Source | Sotio Biotech Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial will assess the MTD and RP2D of SOT102 administered as monotherapy (Part A) and in combination with first-line SoC treatment (mFOLFOX6 with nivolumab and nab-paclitaxel/ gemcitabine; Part B) and efficacy of SOT102 administered as monotherapy (Part C) and in combination with first-line SoC treatment (Part D) in patients with advanced inoperable or metastatic gastric/GEJ adenocarcinoma or inoperable or metastatic pancreatic adenocarcinoma.
Status | Suspended |
Enrollment | 269 |
Est. completion date | June 2025 |
Est. primary completion date | December 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: All Parts (key criteria) - Hematologic: Absolute neutrophil count =1.5×109/L, platelets =100×109/L, hemoglobin =9 g/dL (time since last transfusion =14 days) - Hepatic: Bilirubin =1.5× upper limits of normal (ULN), ALT and AST =2.5×ULN; in case of liver involvement: AST and ALT =5×ULN - Renal: Creatinine clearance =60 mL/min calculated by Cockcroft-Gault formula - Prothrombin time/international normalized ratio (INR) =1.5×ULN - Albumin =3.0 mg/dL - Proteinuria <1 g/24 hours - Eastern Cooperative Oncology Group (ECOG) performance status =1 - Estimated life expectancy =3 months as per investigator's assessment - A female patient is eligible to participate if she is not pregnant, not breastfeeding, not of childbearing potential/ agreed with contraception Part A - Patient has advanced inoperable or metastatic disease - Patient has no better treatment option available - Measurable or non-measurable disease according to RECIST 1.1 - Histological or cytological evidence of adenocarcinoma of the stomach or GEJ or pancreas that is advanced or metastatic Part B (in addition to relevant A criteria) - Histological or cytological evidence of adenocarcinoma of the stomach or GEJ that is advanced or metastatic - Must have HER2-negative tumors (gastric) - Histological or cytological evidence of adenocarcinoma of the pancreas that is advanced or metastatic (pancreas) - Part C (in addition to relevant A criteria) - Must have received at least two prior systemic therapies for advanced or metastatic disease. If HER2 overexpression: must have received anti-HER2 therapy (gastric) - Must have received at least one prior systemic therapy for advanced or metastatic disease (pancreas) Part D (in addition to relevant B criteria) - Histological or cytological evidence of adenocarcinoma of the stomach or GEJ that is advanced inoperable or metastatic - Must have HER2-negative tumors (gastric) - Histological or cytological evidence of adenocarcinoma of the pancreas that is advanced inoperable or metastatic (pancreas) Exclusion Criteria: All Parts (key criteria) - Prior therapy with any agent directed at CLDN18.2 - Patient has received radiation therapy =14 days before day 1 of cycle 1 or has not recovered to grade =1 from treatment-related side effects - Severe preexisting medical conditions as per judgement of the investigator (e.g., active gastric or GEJ ulcer with or without bleeding, complete or incomplete gastric outlet syndrome with persistent or repetitive bleeding) - History of interstitial pneumonitis or pulmonary fibrosis - Symptomatic central nervous system malignancy. Patients with asymptomatic or treated central nervous system metastases may be eligible if they are not treated with corticosteroids or anticonvulsants and the disease is stable for at least 60 days. - Patient has peripheral sensory neuropathy grade =2 - Active infection requiring systemic therapy within =7 days prior to day 1 of cycle 1 - Known history of HIV infection or known active hepatitis B or hepatitis C - History or family history of congenital long QT syndrome - Major surgical intervention =28 days prior to ICF signature or incomplete wound healing after surgical intervention Part B/D (key) - Patients with contraindications to any component of the first-line SoC treatment - Dihydropyrimidine dehydrogenase (DPD) deficiency (gastric) |
Country | Name | City | State |
---|---|---|---|
Belgium | Institut Jules Bordet | Brussels | |
Belgium | Universitair Ziekenhuis Leuven - Campus Gasthuisberg | Leuven | |
Czechia | Masarykuv Onkologický Ústav | Brno | |
France | Institut Gustave Roussy | Paris | |
Spain | VHIO - Vall d'Hebron Institut d'Oncologia | Barcelona | |
Spain | Hospital Universitario HM Sanchinarro | Madrid | |
United States | Cleveland Clinic Main Campus | Cleveland | Ohio |
United States | Washington University School of Medicine in St. Louis | Saint Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Sotio Biotech Inc. |
United States, Belgium, Czechia, France, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Parts C and D (monotherapy and combination with SoC): Relationship between the intensity of CLDN18.2 expression and clinical outcome | Correlation between the intensity of CLDN18.2 expression determined by immunohistochemistry staining, and clinical outcome, determined by disease response as per RECIST 1.1 criteria and OS | From Day 1 of Cycle 1 until the end of SOT102 treatment, assessed up to approximately 4 years | |
Primary | Parts A and B: The definition of the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of SOT102 given as monotherapy and in combination with first-line SoC treatment | MTD is defined as the highest dose level tested below the dose level associated with =33% of dose-limiting toxicity (DLT)-evaluable patients experiencing a DLT. The RP2D will be selected based on evaluation of the totality of all data. | Through Cycles 1-2 (28 days) | |
Primary | Parts C and D: The assessment of the efficacy of SOT102 in monotherapy and in combination with first-line SoC treatment | Efficacy is determined by objective response rate (ORR) determined according to RECIST 1.1 criteria | From Day 1 of Cycle 1 until disease progression or start of new anticancer therapy, whichever is first, assessed up to approximately 4 years | |
Secondary | Parts A and B (monotherapy and combination with SoC): Number of participants with DLTs | Adverse events (AEs) graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 considered DLTs: All grade 5 events not clearly related to disease progression or any other causes Any grade 3 or higher non-hematologic toxicity regardless of duration Hy's law cases Any grade 2 pneumonitis that does not resolve to grade 1 within 3 days of the initiation of maximal supportive care Recurrent grade 2 pneumonitis Grade 4 neutropenia lasting more than 7 days Febrile neutropenia Grade 3 thrombocytopenia with bleeding Grade 4 thrombocytopenia AEs NOT considered DLTs: Grade 3 nausea, vomiting, or diarrhea that can be controlled within 72 hours Grade 3 fatigue less than 5 days Grade 3 or higher correctable electrolyte abnormalities that last less than 72 hours and not associated with clinical complications Grade 3 or higher amylase or lipase not associated with clinical manifestations of pancreatitis |
Through Cycles 1-2 (28 days) | |
Secondary | Parts A and B (monotherapy and combination with SoC): Number of participants with treatment-emergent AEs (TEAEs) | A TEAE is defined as an AE that: emerges during SOT102 treatment, having been absent at the time of pre-treatment (screening), or re-emerges during SOT102 treatment, having been present at the time of pre-treatment (screening), or worsens in severity during SOT102 treatment relative to the pre-treatment state if the AE is continuous. |
From Day 1 of Cycle 1 until 30 (+5) days after the last dose of SOT102, assessed up to approximately 4 years | |
Secondary | Parts A and B (monotherapy and combination with SoC): Number of participants with SOT102-related AEs | Causal relationship (relatedness) of all AEs will be assessed by investigators and classified as follows: Not suspected: It is not plausible that the AE is caused by medication/procedure and a likely alternative explanation exists. No reasonable possibility of a causal or temporal relationship. Suspected: It is plausible that the AE is caused by medication/procedure. Reasonable possibility of a causal relationship. |
From Day 1 of Cycle 1 until 30 (+5) days after the last dose of SOT102, assessed up to approximately 4 years | |
Secondary | Parts A and B (monotherapy and combination with SoC): Number of participants with serious AEs (SAEs) | An SAE is any untoward medical occurrence that at any dose fulfills one or more of the following criteria: Results in death Is immediately life-threatening Results in persistent or significant disability/incapacity Is a congenital anomaly/birth defect Requires inpatient hospitalization or prolongation of existing hospitalization Is another medically significant event defined as an event that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or may require intervention to prevent any of the above listed outcomes |
From the date of the patient's signing the Informed Consent Form (ICF) until 30 (+5) days after the last dose of SOT102, assessed up to approx. 4 years; SAEs with a suspected causal relationship to SOT102 per the investigator's judgment: at any time | |
Secondary | Parts A and B (monotherapy and combination with SoC): Number of participants with AEs leading to premature discontinuation of SOT102 | AEs (intercurrent illness or trial treatment-related toxicity) that would, in the judgment of the investigator, affect assessments of clinical status to a significant degree or require discontinuation of trial treatment | From Day 1 of Cycle 1 until the end of SOT102 treatment, assessed up to approximately 4 years | |
Secondary | Parts A and B (monotherapy and combination with SoC): Number of participants who died | Date of death and immediate and underlying causes of death will be collected. | From the date of the patient's signing the ICF until disease progression or start of new anticancer therapy, whichever is first, assessed up to approximately 4 years | |
Secondary | Parts A and B (monotherapy and combination with SoC): Number of participants with clinical laboratory test abnormalities (coagulation, hematology, clinical chemistry and urinalysis) of grade 3 or higher graded according to NCI CTCAE version 5.0 | The following laboratory parameters will be assessed: Coagulation: prothrombin time, INR Hematology: leukocytes, erythrocytes, hemoglobin, hematocrit, platelets, differential Clinical chemistry: ALT, albumin, ALP, amylase, AST, bilirubin, blood urea nitrogen or blood urea, calcium, creatinine, glucose (fasting), LDH, lipase, magnesium, potassium, sodium, TSH (gastric adenocarcinoma only) Urinalysis: blood, glucose, ketones, pH, protein, specific gravity, urine leukocyte esterase |
From the date of the patient's signing the ICF until 30 (+5) days after the last dose of SOT102, assessed up to approximately 4 years | |
Secondary | Parts A and B (monotherapy and combination with SoC): Characterization of pharmacokinetics (PK) of total SOT102 and its derivates | Assessment of concentration of SOT102 and its derivates at various timepoints | From Day 1 of Cycle 1 until Day 1 of Cycle 5 | |
Secondary | Parts A and B (monotherapy and combination with SoC): Evidence of SOT102 activity in monotherapy in individual patients | Detection of anecdotal tumor response in individual patient, as per RECIST 1.1 criteria | From Day 1 of Cycle 1 until disease progression or start of new anticancer therapy, whichever is first, assessed up to approximately 4 years | |
Secondary | Parts A and B (monotherapy and combination with SoC): Number of participants with antibodies against SOT102 | Identification of patients who develop detectable antibodies against any part of SOT102 | From Day 1 of Cycle 1 until 30 (+5) days after the last dose of SOT102, assessed up to approximately 4 years | |
Secondary | Parts C and D (monotherapy and combination with SoC): Duration of response (DoR) according to RECIST 1.1 | The DoR is defined as the time from the first achieved response (complete or partial, confirmed) until the first date of radiological progression or death. | From Day 1 of Cycle 1 until disease progression or start of new anticancer therapy, whichever is first, assessed up to approximately 4 years | |
Secondary | Parts C and D (monotherapy and combination with SoC): Progression-free survival (PFS) according to RECIST 1.1 | PFS is defined as the time from trial enrolment until the first date of radiological progression or death. | From Day 1 of Cycle 1 until disease progression or start of new anticancer therapy, whichever is first, assessed up to approximately 4 years | |
Secondary | Part C (monotherapy): Clinical benefit rate (CBR) according to RECIST 1.1 | The CBR is defined as the number of complete responses, partial responses, and stable diseases from all evaluable best overall responses. | From Day 1 of Cycle 1 until disease progression or start of new anticancer therapy, whichever is first, assessed up to approximately 4 years | |
Secondary | Parts C and D (monotherapy and combination with SoC): Overall survival (OS) | OS is defined as the time from eligibility verification until the date of death. | From Day 1 of Cycle 1 until the end of the trial, assessed up to approximately 4 years | |
Secondary | Parts C and D (monotherapy and combination with SoC): Number of participants with TEAEs | A TEAE is defined as an AE that: emerges during SOT102 treatment, having been absent at the time of pre-treatment (screening), or re-emerges during SOT102 treatment, having been present at the time of pre-treatment (screening), or worsens in severity during SOT102 treatment relative to the pre-treatment state if the AE is continuous. |
From Day 1 of Cycle 1 until 30 (+5) days after the last dose of SOT102, assessed up to approximately 4 years | |
Secondary | Parts C and D (monotherapy and combination with SoC): Number of participants with SOT102-related AEs | Causal relationship (relatedness) of all AEs will be assessed by investigators and classified as follows: Not suspected: It is not plausible that the AE is caused by medication/procedure and a likely alternative explanation exists. No reasonable possibility of a causal or temporal relationship. Suspected: It is plausible that the AE is caused by medication/procedure. Reasonable possibility of a causal relationship. |
From Day 1 of Cycle 1 until 30 (+5) days after the last dose of SOT102, assessed up to approximately 4 years | |
Secondary | Parts C and D (monotherapy and combination with SoC): Number of participants with SAEs | An SAE is any untoward medical occurrence that at any dose fulfills one or more of the following criteria: Results in death Is immediately life-threatening Results in persistent or significant disability/incapacity Is a congenital anomaly/birth defect Requires inpatient hospitalization or prolongation of existing hospitalization Is another medically significant event defined as an event that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or may require intervention to prevent any of the above listed outcomes |
From the date of the patient's signing the ICF until 30 (+5) days after the last dose of SOT102, assessed up to approximately 4 years; SAEs with a suspected causal relationship to SOT102 per the investigator's judgment: at any time | |
Secondary | Parts C and D (monotherapy and combination with SoC): Number of participants with AEs leading to premature discontinuation of SOT102 | AEs (intercurrent illness or trial treatment-related toxicity) that would, in the judgment of the investigator, affect assessments of clinical status to a significant degree or require discontinuation of trial treatment | From Day 1 of Cycle 1 until the end of SOT102 treatment, assessed up to approximately 4 years | |
Secondary | Parts C and D (monotherapy and combination with SoC): Number of participants who died | Date of death and immediate and underlying causes of death will be collected. | From the date of the patient's signing the ICF until the end of the trial, assessed up to approximately 4 years | |
Secondary | Parts C and D (monotherapy and combination with SoC): Number of participants with clinical laboratory test abnormalities (coagulation, hematology, clinical chemistry and urinalysis) of grade 3 or higher graded according to NCI CTCAE version 5.0 | The following laboratory parameters will be assessed: Coagulation: prothrombin time, INR Hematology: leukocytes, erythrocytes, hemoglobin, hematocrit, platelets, differential Clinical chemistry: ALT, albumin, ALP, amylase, AST, bilirubin, blood urea nitrogen or blood urea, calcium, creatinine, glucose (fasting), LDH, lipase, magnesium, potassium, sodium, TSH (gastric adenocarcinoma only) Urinalysis: blood, glucose, ketones, pH, protein, specific gravity, urine leukocyte esterase |
From the date of the patient's signing the ICF until 30 (+5) days after the last dose of SOT102, assessed up to approximately 4 years | |
Secondary | Parts C and D (monotherapy and combination with SoC, patients with gastric cancer): Patient-reported quality of life questionnaire EORTC QLQ-C30 scores | To determine the effect of trial intervention on the quality of life. | From the date of the patient's signing the ICF until 30 (+5) days after the last dose of SOT102, assessed up to approximately 4 years | |
Secondary | Parts C and D (monotherapy and combination with SoC, patients with gastric cancer): Patient-reported quality of life questionnaire EORTC QLQ-STO22 scores | To determine the effect of trial intervention on the quality of life. | From the date of the patient's signing the ICF until 30 (+5) days after the last dose of SOT102, assessed up to approximately 4 years | |
Secondary | Parts C and D (monotherapy and combination with SoC, patients with pancreatic cancer): Patient-reported quality of life questionnaire EORTC QLQ-C30 scores | To determine the effect of trial intervention on the quality of life. | From the date of the patient's signing the ICF until 30 (+5) days after the last dose of SOT102, assessed up to approximately 4 years | |
Secondary | Parts C and D (monotherapy and combination with SoC, patients with pancreatic cancer): Patient-reported quality of life questionnaire EORTC QLQ-PAN26 scores | To determine the effect of trial intervention on the quality of life. | From the date of the patient's signing the ICF until 30 (+5) days after the last dose of SOT102, assessed up to approximately 4 years | |
Secondary | Parts C and D (monotherapy and combination with SoC): Patient-reported quality of life questionnaire EQ-5D-3L scores | To determine the effect of trial intervention on the quality of life. | From the date of the patient's signing the ICF until the end of the trial, assessed up to approximately 4 years | |
Secondary | Parts C and D (monotherapy and combination with SoC): Characterization of PK of total SOT102 and its derivates | Assessment of concentration of SOT102 and its derivates at various timepoints | From Day 1 of Cycle 1 until the end of SOT102 treatment, assessed up to approximately 4 years | |
Secondary | Parts C and D (monotherapy and combination with SoC): Number of participants with antibodies against SOT102 | Identification of patients who develop detectable antibodies against any part of SOT102 | From Day 1 of Cycle 1 until the end of SOT102 treatment, assessed up to approximately 4 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05305001 -
Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Recruiting |
NCT04927780 -
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
|
Phase 3 | |
Recruiting |
NCT06054984 -
TCR-T Cells in the Treatment of Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Terminated |
NCT03140670 -
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
|
Phase 2 | |
Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT05168527 -
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05391126 -
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
|
N/A | |
Terminated |
NCT03300921 -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT03153410 -
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
|
Early Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05679583 -
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT04183478 -
The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer
|
Phase 2/Phase 3 | |
Terminated |
NCT03600623 -
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
|
Early Phase 1 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Completed |
NCT04290364 -
Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study
|